Fundraising FoxMelinta Therapeutics INC /New
New Haven, US · Delaware corporation
Find your way into Melinta Therapeutics INC /New
Sign up to see every warm intro you have to Melinta Therapeutics INC /New
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Melinta Therapeutics INC /New team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SC
Sue CammarataExecutive Vice President and Chief Medical Officer
DW
Daniel WechslerDirector, President and Chief Executive Officer
ED
Erin DuffyExecutive Vice President and Chief Scientific Officer
PE
Paul EstremExecutive
Board
GK
Garheng KongBoard director
KT
Kevin T. FerroChairman of the Board
TP
Thomas P. KoestlerBoard director
CG
Cecilia GonzaloBoard director
JH
John H. JohnsonBoard director
DG
David GillBoard director
DZ
David ZaccardelliBoard director
JJ
Jay J. Galeota, Jr.Board director
Reported raises · per SEC filings
Form D private placements$270.7M disclosed across 2 rounds · 2017–2018
▶$137.8MraisedJan 2018 · 9 investors · PharmaceuticalsRule 506(b)
▶$137.8MraisedJan 2018 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John H. JohnsonDirector
- David GillDirector
- Garheng KongDirector
- David ZaccardelliDirector
- Sue CammarataExecutive Officer
- Kevin T. FerroDirector
- Thomas P. KoestlerDirector
- Jay J. Galeota, Jr.Director
- Daniel WechslerExecutive Officer, Director
- Cecilia GonzaloDirector
- Erin DuffyExecutive Officer
- Paul EstremExecutive Officer
- Offering amount
- $137.8M
- Amount sold
- $137.8M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$132.9MraisedNov 2017 · 39 investors · PharmaceuticalsRule 506(b)
▶$132.9MraisedNov 2017 · 39 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David ZaccardelliDirector
- Cecilia GonzaloDirector
- David GillDirector
- Jay GaleotaDirector
- Sue CammarataExecutive Officer
- Garheng KongDirector
- John JohnsonDirector
- Thomas P. KoestlerDirector
- Daniel WechslerExecutive Officer, Director
- Erin DuffyExecutive Officer
- John TemperatoExecutive Officer
- Paul EstremExecutive Officer
- Kevin FerroDirector
- Offering amount
- $132.9M
- Amount sold
- $132.9M
- First sale
- Nov 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Melinta Therapeutics INC /New raised?
- Melinta Therapeutics INC /New has disclosed $270.7M raised across 2 rounds.
- Where is Melinta Therapeutics INC /New headquartered?
- Melinta Therapeutics INC /New is headquartered in New Haven, US.